Biocept Signs Deal to Sell $2.2M in Stock, Warrants

Aug 10, 2017

NEW YORK (GenomeWeb) – Biocept today said that it has signed an agreement to sell $2.2 million in stock and warrants to Hong Kong-based investment group Ally Bridge LB Healthcare Master Fund Limited.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Featured White Papers

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

May

22

Featured Webinar

From Qualitative to Quantitative: Experiences with a cfDNA Assay in Metastatic Breast Cancer Research

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences will discuss her team’s work using liquid biopsy technology for breast cancer research.

Jun

05

Featured Webinar

Text Mining at Sanofi for Genotype-Phenotype Associations in Multiple Sclerosis

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun

14

Featured Webinar

Overcoming Challenges in Hematological Genomic Testing with Advanced AI

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Main menu